- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON 05.11.2025 | 73 | Xetra Newsboard | The following instruments on XETRA do have their first trading 05.11.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.11.2025
Aktien
1 US05374V1089 Avio S.p.A. ADR
2 NO0003087603... ► Artikel lesen | |
| 17.10. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - ORPHAN-DRUG DESIGNATION OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) FOR THE TREATMENT OF ... | - | HKEx | ||
| 09.10. | Henlius's gastric cancer drug meets phase 3 trial endpoint | 2 | Investing.com | ||
| 09.10. | Henlius: Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission | 85 | PR Newswire | The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA)... ► Artikel lesen | |
| 09.10. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE PHASE 3 CLINICAL STUDY OF HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ADJUVANT ... | 2 | HKEx | ||
| 30.09. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE 1B/2 CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN ... | 1 | HKEx | ||
| 30.09. | HENLIUS (02696): INTERIM REPORT 2025 | 2 | HKEx | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 29.09. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF AN IPILIMUMAB BIOSIMILAR HLX13 (RECOMBINANT ANTI-CTLA-4 FULLY HUMAN ... | - | HKEx | ||
| 26.09. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF A BIOSIMILAR OF ... | 2 | HKEx | ||
| 19.09. | Organon & Co.: Die Europäische Kommission (EK) genehmigt BILDYOS (Denosumab) von Henlius und Organon sowie BILPREVDA (Denosumab), Biosimilars zu PROLIA (Denosumab) bzw. XGEVA (Denosumab) | 549 | Business Wire | Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute die Erteilung der Marktzulassung durch die Europäische Kommission (EK) für die BILDYOS (Denosumab)-Injektion 60 mg/ml und... ► Artikel lesen | |
| 19.09. | Organon & Co.: European Commission (EC) Approves Henlius and Organon's BILDYOS (denosumab) and BILPREVDA (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively | 425 | Business Wire | Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS (denosumab) injection 60 mg/mL and BILPREVDA... ► Artikel lesen | |
| 19.09. | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - EUROPEAN COMMISSION (EC) APPROVED TWO PRODUCTS OF HLX14 (DENOSUMAB, EUROPEAN TRADE NAMES: BILDYOS AND ... | - | HKEx | ||
| 18.09. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT IN AUSTRALIA HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTRE PHASE 2 CLINICAL STUDY OF HLX43 FOR ... | - | HKEx | ||
| 16.09. | Henlius Biotech in talks with J&J, Roche on cancer drug: report | 29 | Seeking Alpha | ||
| 08.09. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF A BIOSIMILAR OF PEMBROLIZUMAB HLX17 (RECOMBINANT HUMANISED ANTI-PD-1 ... | 1 | HKEx | ||
| 02.09. | Organon and Henlius get FDA nod for Amgen biosimilars | 37 | Seeking Alpha | ||
| 02.09. | HENLIUS (02696): EXCHANGE'S DISCIPLINARY ACTION AGAINST SHANGHAI HENLIUS BIOTECH, INC. (STOCK CODE: 2696) AND ONE FORMER DIRECTOR | - | HKEx | ||
| 01.09. | Shanghai Henlius Biotech Receives Approval Letter From FDA For BILDYOS, BILPREVDA | 1 | RTTNews | ||
| 01.09. | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) APPROVED TWO PRODUCTS OF HLX14 (DENOSUMAB-NXXP, ... | 1 | HKEx | ||
| 29.08. | HENLIUS (02696): GRANTS OF OPTIONS AND RSUS | - | HKEx |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,488 | -8,44 % | EQS-News: Evotec SE: Bekanntgabe der Ergebnisse für die ersten neun Monate 2025 am 05. November 2025 | EQS-News: Evotec SE
/ Schlagwort(e): 9-Monatszahlen
Evotec SE: Bekanntgabe der Ergebnisse für die ersten neun Monate 2025 am 05. November 2025
29.10.2025 / 09:45 CET/CEST
Für... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,50 | 0,00 % | Tarsus outlines $140M-$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress | ||
| HARMONY BIOSCIENCES | 30,720 | 0,00 % | Harmony Biosciences raises 2025 revenue outlook to $845M-$865M amid record WAKIX patient growth and advancing pipeline | ||
| AVIDITY BIOSCIENCES | 69,83 | 0,00 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| QIAGEN | 38,180 | -3,77 % | Märkte am Morgen: AMD, Uber, Super Micro Computer, Amgen, Qiagen | Nach dem starken Monatsauftakt hat der DAX spürbar an Schwung verloren. Der Leitindex fiel am Dienstag zeitweise um zwei Prozent, konnte sich aber leicht erholen und schloss 0,76 Prozent tiefer bei... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 17,325 | -3,59 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,000 | 0,00 % | Recursion Pharmaceuticals Q3 2025 Earnings Preview | ||
| PRAXIS PRECISION MEDICINES | 171,86 | -5,57 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| UPSTREAM BIO | 25,040 | +0,08 % | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,140 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug... ► Artikel lesen | |
| PRIME MEDICINE | 4,300 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer | CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,620 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,495 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,710 | 0,00 % | Beam Therapeutics GAAP EPS of -$1.10 misses by $0.09, revenue of $9.69M misses by $3.03M | ||
| DYNE THERAPEUTICS | 21,505 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen |
Das Unternehmen SHANGHAI HENLIUS BIOTECH INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,781 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.